Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication of YIKAIDA submitted by Fosun Kite Biotechnology Co., Ltd. (hereinafter referred to as Fosun Kite) was approved for review and included in the list for priority review. Consequently, adult patients suffering from large B cell lymphoma and not responding to first-line immunochemo therapy or relapsing within 12 months after first-line immunochemo therapy are expected to enjoy such benefits earlier.
